ABBV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ABBV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AbbVie's other long-term liabilities for the quarter that ended in Dec. 2023 was $30,789 Mil.
AbbVie's quarterly other long-term liabilities declined from Jun. 2023 ($32,294 Mil) to Sep. 2023 ($31,644 Mil) and declined from Sep. 2023 ($31,644 Mil) to Dec. 2023 ($30,789 Mil).
AbbVie's annual other long-term liabilities increased from Dec. 2021 ($25,548 Mil) to Dec. 2022 ($29,017 Mil) and increased from Dec. 2022 ($29,017 Mil) to Dec. 2023 ($30,789 Mil).
The historical data trend for AbbVie's Other Long-Term Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbbVie Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Other Long-Term Liabilities | Get a 7-Day Free Trial | - | - | - | - | - |
AbbVie Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Other Long-Term Liabilities | Get a 7-Day Free Trial | - | - | - | - | - |
Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.
Thank you for viewing the detailed overview of AbbVie's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.
Nicholas Donoghoe | officer: SVP, Enterprise Innovation | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Susan E Quaggin | director | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Jennifer L. Davis | director | 1 PROCTER & GAMBLE PLAZA, CINCINNATI OH 45202 |
Richard A Gonzalez | officer: Chairman of the Board and CEO | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Elaine K. Sorg | officer: Sr. V.P., U.S. Commercial Ops. | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Perry C Siatis | officer: EVP, GC and Secretary | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Jeffrey Ryan Stewart | officer: SVP, US Commercial Operations | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Kevin K Buckbee | officer: SVP, Controller | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Scott T Reents | officer: SVP, Chief Financial Officer | 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Azita Saleki-gerhardt | officer: SVP, Operations | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Carrie C Strom | officer: SVP & Pres Global Allerg Aesth | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Roxanne S Austin | director | 200 N SEPULVEDA BLVD, PO BOX 956 MS ES/001/A102, EL SEGUNDO CA 90245 |
Timothy J. Richmond | officer: EVP, Chief HR Officer | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Michael Severino | officer: EVP, R&D and CSO | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064 |
Henry O Gosebruch | officer: Chief Strategy Officer | 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092 |
From GuruFocus
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-23-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.